Antiangiogenic and antivascular therapy for cancer

Current Opinion in Pharmacology

Volumn 1, Issue 4, 2001, Pages 378-384

  Taraboletti, Giulia ^a   Margosio, Barbara ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

Antineoplastic therapy; Antivascular therapy; Cancer Biology; Growth factors; Inhibitors of angiogenesis; Matrix metalloproteinases; Pharmacology; Tumor angiogenesis; Vascular targeting

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANIMAL; BLOOD FLOW; BLOOD VESSEL; DRUG EFFECT; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD VESSELS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 0035434591     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00065-0     Document Type: Review

References (61)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
3. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
4. Mauceri H.J., Hanna N.N., Beckett M.A., Gorski D.H., Staba M.J., Stellato K.A., Bigelow K., Heimann R., Gately S., Dhanabal M., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 394:1998;287-291.
5. Aviezer D., Cotton S., David M., Segev A., Khaselev N., Galili N., Gross Z., Yayon A. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res. 60:2000;2973-2980.
6. Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., Wieczorek A.A., Ogura Y., McConkey D.J., Drazan K.E., et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 61:2001;1464-1468.
7. Matsushita S., Nitanda T., Furukawa T., Sumizawa T., Tani A., Nishimoto K., Akiba S., Miyadera K., Fukushima M., Yamada Y., et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 59:1999;1911-1916.
8. Buckley C.D., Pilling D., Henriquez N.V., Parsonage G., Threlfall K., Scheel-Toellner D., Simmons D.L., Akbar A.N., Lord J.M., Salmon M. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 397:1999;534-539.
9. 5 integrin receptor antagonist. Cancer Res. 61:2001;2232-2238.
10. Liao F., Li Y., O'Connor W., Zanetta L., Bassi R., Santiago A., Overholser J., Hooper A., Mignatti P., Dejana E., et al. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res. 60:2000;6805-6810.
11. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
12. Hagedorn M., Zilberberg L., Lozano R.M., Cuevas P., Canron X., Redondo-Horcajo M., Gimenez-Gallego G., Bikfalvi A. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 15:2001;550-552.
13. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 285:1999;245-248.
14. Yi M., Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci USA. 98:2001;620-624.
15. 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 275:2000;23745-23750.
16. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K., et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60:2000;2520-2526.
17. Petitclerc E., Boutaud A., Prestayko A., Xu J., Sado Y., Ninomiya Y., Sarras M.P. Jr, Hudson B.G., Brooks P.C. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem. 275:2000;8051-8061.
18. Struman I., Bentzien F., Lee H., Mainfroid V., D'Angelo G., Goffin V., Weiner R.I., Martial J.A. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA. 96:1999;1246-1251.
19. Taraboletti G., Morbidelli L., Donnini S., Parenti A., Granger H.J., Giavazzi R., Ziche M. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 14:2000;1674-1676.
20. Brown P.D. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Invest Drugs. 9:2000;2167-2177.
21. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93:2001;178-193.
22. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 91:1997;439-442.
23. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 103:1999;1237-1241.
24. Hotary K., Allen E., Punturieri A., Yana I., Weiss S.J. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol. 149:2000;1309-1323. This study demonstrates the importance of membrane-type MMPs, rather than soluble MMPs, in cell migration and morphogenesis. Therefore, membrane-type MMPs appear to be better candidates than soluble MMPs as targets for antiangiogenic therapy.
25. Quaranta V. Cell migration through extracellular matrix: membrane-type metalloproteinases make the way. J Cell Biol. 149:2000;1167-1170.
26. Zhu W.H., Guo X., Villaschi S., Francesco Nicosia R. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab Invest. 80:2000;545-555.
27. Zhou Z., Apte S.S., Soininen R., Cao R., Baaklini G.Y., Rauser R.W., Wang J., Cao Y., Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA. 97:2000;4052-4057.
28. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA. 98:2001;119-124.
29. Elkin M., Miao H.Q., Nagler A., Aingorn E., Reich R., Hemo I., Dou H.L., Pines M., Vlodavsky I. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 14:2000;2477-2485.
30. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 5:1999;793-802.
31. Dubowchik G.M., Walker M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther. 83:1999;67-123.
32. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 5:1999;1418-1423.
33. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
34. Miller K.D., Sweeney C.J., Sledge G.W. Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 19:2001;1195-1206.
35. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
36. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 105:2000;R15-R24.
37. Chaplin D.J., Dougherty G.J. Tumour vasculature as a target for cancer therapy. Br J Cancer. 80:(suppl 1):1999;57-64.
38. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.Y., Smulson M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58:1998;4510-4514.
39. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., et al. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202. This is the first systematic analysis of gene expression in tumor endothelium. Gene expression profiles of highly purified endothelial cells from human colorectal carcinomas and endothelial cells from normal tissues were compared using serial analysis of gene expression (SAGE). The analysis led to the identification of several panendothelial-cell markers (expressed on all endothelial cells, but not on other cell types) and of genes differentially expressed on endothelial cells derived from tumor versus normal tissues (genes upregulated in tumor endothelium or with higher expression in normal endothelium). Many of these genes still need to be characterized.
40. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 97:2000;14608-14613.
41. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 155:1999;739-752.
42. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 7:2001;192-198. See annotation to [45•].
43. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 7:2001;186-191. See annotation to [45•].
44. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D.G., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20:2001;672-682. See annotation to [45•].
45. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61:2001;1786-1790. These studies [42•,43•,44•,45•] demonstrate a causal link between tumor lymphangiogenesis and metastasis. In different tumor models lymphatic vessels were more abundant in tumors generated by tumor cells overexpressing VEGF-C and VEGF-D. These tumors were more metastatic.
46. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., Kearne M., Magner M., Isner J.M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 85:1999;221-228.
47. Lyden D., Young A.Z., Zagzag D., Yan W., Gerald W., O'Reilly R., Bader B.L., Hynes R.O., Zhuang Y., Manova K., et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 401:1999;670-677.
48. Ito H., Rovira I.I., Bloom M.L., Takeda K., Ferrans V.J., Quyyumi A.A., Finkel T. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. 59:1999;5875-5877.
49. Nesbit M. Abrogation of tumor vasculature using gene therapy. Cancer Metastasis Rev. 19:2000;45-49.
50. Nguyen J.T., Wu P., Clouse M.E., Hlatky L., Terwilliger E.F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 58:1998;5673-5677.
51. Liu Y., Thor A., Shtivelman E., Cao Y., Tu G., Heath T.D., Debs R.J. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem. 274:1999;13338-13344.
52. Giavazzi R., Giuliani R., Coltrini D., Bani M.R., Ferri C., Sennino B., Tosatti M.P., Stoppacciaro A., Presta M. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res. 61:2001;309-317.
53. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:1999;808-812. Different schedules of treatment with four antiangiogenic compounds were investigated in a transgenic mouse model of pancreatic islet multistage carcinogenesis (RIP1-Tag2). The MMP inhibitor BB-94 and endostatin were most effective when treatment was given at the hyperplastic stage, to block the angiogenic switch, or on small, asymptomatic tumors. They were not effective in mice with a substantial tumor burden. AGM-1470 (TNP-470, see Table 1) did not prevent the angiogenic switch, but was effective on mice bearing small, vascularized tumors. Interestingly, only treatment with AGM-1470 and with the combination of endostatin and angiostatin caused a regression of large tumors, although all four compounds were effective in increasing the survival of mice.
54. Giavazzi R., Garofalo A., Ferri C., Lucchini V., Bone E.A., Chiari S., Brown P.D., Nicoletti M.I., Taraboletti G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 4:1998;985-992.
55. Liu L., Anderson W.F., Beart R.W., Gordon E.M., Hall F.L. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. J Virol. 74:2000;5320-5328.
56. Scherpereel A., Wiewrodt R., Christofidou-Solomidou M., Gervais R., Murciano J.C., Albelda S.M., Muzykantov V.R. Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting. FASEB J. 15:2001;416-426.
57. Ran S., Gao B., Duffy S., Watkins L., Rote N., Thorpe P.E. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 58:1998;4646-4653.
58. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
59. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 5:1999;1032-1038.
60. Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 61:2001;711-716.
61. Arora N., Masood R., Zheng T., Cai J., Smith D.L., Gill P.S. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 59:1999;183-188.